Fas-associating death domain protein overexpression induces apoptosis in lung cancer cells

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 6, 2003, Pages 1336-1342

  Kim, Peter K M ^a   Park, Sang Youel ^a   Koty, Patrick P ^a   Hua, Yun ^a   Luketich, James D ^a   Billiar, Timothy R ^a   Sellke, Frank W ^b   Patterson, G Alexander ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NW607 MUH ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 8; CRYSTAL VIOLET; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEIN; PROTEIN HYDROLYSATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; VIRUS INFECTION; WESTERN BLOTTING; WILD TYPE;

EID: 0038310766     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(02)73227-3     Document Type: Article

References (31)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Allen RT, Hunter WJ III, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 1997;37:215-28.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-62.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153-64.
5. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505-12.
6. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APOI contains a sequence motif related to the death domain. J Biol Chem. 1995;270:7795-8.
7. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-65.
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-8.
9. Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J Biol Chem. 1998;273:4345-9.
10. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998; 273:2926-30.
11. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-6.
12. Takahashi Y, Geller DA, Gambotto A, Watkins SC, Fung JJ, Murase N. Adenovirus-mediated gene therapy to liver grafts: successful gene transfer by donor pretreatment. Surgery. 2000; 128:345-52.
13. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem. 1999;274: 17325-33.
14. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-9.
15. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17:2941-53.
16. Guchelaar HJ, Vermes A, Vermes I, Haanen C. Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci. 1997;19:119-25.
17. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20:1063-75.
18. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1-4.
19. Newton K, Strasser A. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling: implications for cancer therapy. J Exp Med. 2000: 191:195-200.
20. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407:810-6.
21. Peter ME. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Differ. 2000;7:759-60.
22. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102-10.
23. Park SY, Billiar TR, Seol DW. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun. 2002;291:150-3.
24. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-63.
25. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999;59:5683-86.
26. McDonald ER III, Chui PC, Martelli PF, Dicker DT, El Deiry WS. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem. 2001;276:14939-45.
27. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703.
28. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, et al. Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol. 2001;28(Suppl 14):50-6.
29. Dubensky TW. (Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease. Cancer Cell. 2002;1:307-9.
30. Kim PK, Wang Y, Gambotto A, Kim YM, Weller R, Zuckerbraun BS, et al. Hepatocyte Fas-associating death domain protein/mediator of receptor-induced toxicity (FADD/MORT1) levels increase in response to pro-apoptotic stimuli. J Biol Chem. 2002;277:38855-62.
31. Kim PK, Weller R, Hua Y, Billiar TR. Ultraviolet irradiation increases FADD protein in apoptotic human keratinocytes. Biochem Biophys Res Commun. 2003;302:290-5.